SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Dante J. Pieramici, MD, overviews pharmacokinetics and safety data for sozinibercept.
Sozinibercept (Opthea), formerly known as OPT-302, is a VEGF-C/D “trap” inhibitor that has demonstrated improved vision and anatomic outcomes in patients with wet age-related macular degeneration when used in combination with VEGF-A inhibitors, according to Pieramici.
“This drug seems to be very safe when used in combination,” he said. “There was really no additional ocular or systemic safety events